Author details

Full Name

Michael G Joyce

Affiliation

ORCID

Career Start Year

2004

Papers

103

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36737435	Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity.	Nat Commun	2023
37561630	Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopes.	Cell Rep	2023
37023746	Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques.	Cell Rep Med	2023
37395646	Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity.	J Virol	2023
36934088	SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodies.	NPJ Vaccines	2023
34914540	A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates.	Sci Transl Med	2022
36306784	Epstein-Barr virus gH/gL has multiple sites of vulnerability for virus neutralization and fusion inhibition.	Immunity	2022
35632473	A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine Is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) Model.	Vaccines (Basel)	2022
36417525	Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFN.	Sci Adv	2022
36679887	Unglycosylated Soluble SARS-CoV-2 Receptor Binding Domain (RBD) Produced in Combined with the Army Liposomal Formulation Containing QS21 (ALFQ) Elicits Neutralizing Antibodies against Mismatched Variants.		2022
34470866	Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques.	Proc Natl Acad Sci U S A	2021
34013273	SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.	bioRxiv	2021
33851155	Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques.	bioRxiv	2021
33791694	Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates.	bioRxiv	2021
34159328	A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters.	bioRxiv	2021
33674699	In vitro and in vivo inhibition of malaria parasite infection by monoclonal antibodies against Plasmodium falciparum circumsporozoite protein (CSP).	Scientific Reports	2021
33662277	B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodies.		2021
33453152	Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth.	Immunity	2021
34135892	Sequence-Signature Optimization Enables Improved Identification of Human HV6-1-Derived Class Antibodies That Neutralize Diverse Influenza A Viruses.	Front Immunol	2021
34086838	Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates.	PLoS Pathogens	2021
34919799	SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.	Cell Rep	2021
34903722	SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses.	NPJ Vaccines	2021
34551978	Interprotomer disulfide-stabilized variants of the human metapneumovirus fusion glycoprotein induce high titer-neutralizing responses.	Proceedings of the National Academy of Sciences of the United States of America	2021
34716452	Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations.	Nat Immunol	2021
34711815	A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge.	NPJ Vaccines	2021
32835602	Novel monoclonal antibodies to the SERINC5 HIV-1 restriction factor detect endogenous andvirion-associated SERINC5.	mAbs	2020
32015557	Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor.	Nat Med	2020
31996483	HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions.	JCI insight	2020
32877670	Identification and Structure of a Multidonor Class of Head-Directed Influenza-Neutralizing Antibodies Reveal the Mechanism for Its Recurrent Elicitation.	Cell Rep	2020
32649880	Need for Speed: From Human SARS-CoV-2 Samples to Protective and Efficacious Antibodies in Weeks.	Cell	2020
32868447	A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants.	Proc Natl Acad Sci U S A	2020
31004012	Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine.	Sci Immunol	2019
31893251	Crystal Structure and Immunogenicity of the DS-Cav1-Stabilized Fusion Glycoprotein From Respiratory Syncytial Virus Subtype B.	Pathogens and Immunity	2019
30980067	Author Correction: Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses.	Nature Immunology	2019
31174408	Correction: Trinh, H.V., et al. Humoral Response to the HIV-1 Envelope V2 Region in a Thai Early Acute Infection Cohort. 2019, , 365.	Cells	2019
30808695	Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages.	mBio	2019
30860010	Global Outbreaks and Origins of a Chikungunya Virus Variant Carrying Mutations Which May Increase Fitness for : Revelations from the 2016 Mandera, Kenya Outbreak.	American Journal of Tropical Medicine and Hygiene	2019
29514901	Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape.	J Virol	2018
30403372	Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core.	Elife	2018
30552024	Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier.	Immunity	2018
29451984	Two-Component Ferritin Nanoparticles for Multimerization of Diverse Trimeric Antigens.	ACS Infect Dis	2018
28275193	Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity.	Journal of Virology	2017
28445724	Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation.	Cell Rep	2017
28747530	Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies.	Proceedings of the National Academy of Sciences of the United States of America	2017
28878010	Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge.	Science Translational Medicine	2017
28783708	Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans.	Science immunology	2017
29021918	Protection of calves by a prefusion-stabilized bovine RSV F vaccine.	npj Vaccines	2017
28514685	Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop.	Immunity	2017
29212041	Soluble Prefusion Closed DS-SOSIP.664-Env Trimers of Diverse HIV-1 Strains.	Cell Reports	2017
29281818	Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models.	Cell Reports	2017